Po­laris is piec­ing to­geth­er a new, $400M-plus biotech fund as good times roll

Back in 2014, I asked MIT’s Bob Langer what dis­tin­guished Po­laris Part­ners – a ven­ture group that rou­tine­ly backed the new com­pa­nies mold­ed out of the work done in his lab – in a busy field.

“Great judg­ment,” Langer shot back. “Al­so treat­ing peo­ple great, with many peo­ple work­ing with them a 2nd, 3rd, 4th time.”

Fair­ly soon, Po­laris’ ven­ture crew should have the mon­ey in hand to make it a fifth time. The ven­ture group filed doc­u­ments with the SEC ear­li­er this week that pegs its next fund at $400 mil­lion — though it’s a mark of hon­or among biotech VCs to make that the base fig­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.